Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies.
AMI-system
abiraterone acetate
food effect
lipid digestion
permeability
rat in situ intestinal perfusion
solubility
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
30
03
2022
revised:
23
04
2022
accepted:
25
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
The anticancer agent abiraterone suffers from an extensive positive food effect after oral intake of the prodrug abiraterone acetate (Zytiga). The underlying processes determining postprandial abiraterone absorption were investigated in this study. The impact of lipids and lipid digestion products on (i) the solubility of abiraterone acetate and abiraterone, (ii) the conversion of abiraterone acetate to abiraterone, and (iii) the passive permeation of abiraterone was determined in vitro. The interaction of abiraterone acetate and abiraterone with vesicles and colloidal structures in the simulated fed state media containing undigested lipids and lipid digestion products enhanced the solubility of both compounds but limited the esterase-mediated hydrolysis of abiraterone acetate and the potential of abiraterone to permeate. Rat in situ intestinal perfusion experiments with a suspension of abiraterone acetate in static fed state simulated media identified abiraterone concentrations in the perfusate as the main driving force for absorption. However, experiments with ongoing lipolysis in the perfusate highlighted the importance of including lipid digestion as a dynamic process when studying postprandial abiraterone absorption. Future research may employ the in situ perfusion model to study postprandial drug absorption from a dynamic lipolysis-mediated intestinal environment to provide reference data for the optimisation of relevant in vitro models to evaluate food effects.
Identifiants
pubmed: 35631538
pii: pharmaceutics14050952
doi: 10.3390/pharmaceutics14050952
pmc: PMC9143506
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Research Foundation - Flanders
ID : G078417N
Références
Mol Pharm. 2016 Oct 3;13(10):3484-3493
pubmed: 27576295
Eur J Pharm Sci. 2018 Jul 1;119:219-233
pubmed: 29660464
Eur J Pharm Biopharm. 2018 Aug;129:104-110
pubmed: 29802985
Int J Pharm. 2020 Mar 15;577:119069
pubmed: 31981706
J Pharm Sci. 2016 Feb;105(2):673-681
pubmed: 26228456
Eur J Pharm Sci. 2022 Jan 1;168:106043
pubmed: 34662708
Xenobiotica. 2013 Apr;43(4):379-89
pubmed: 23020788
Mol Pharm. 2012 Feb 6;9(2):237-47
pubmed: 22136289
Eur J Pharm Sci. 2019 Jun 15;134:31-59
pubmed: 30974173
Eur J Pharm Biopharm. 2015 Feb;90:1-7
pubmed: 25592324
Int J Pharm. 2015 Jan 30;478(2):665-81
pubmed: 25448559
J Pharm Sci. 2016 Sep;105(9):2974-2981
pubmed: 27061460
J Pharm Sci. 2018 Jan;107(1):250-256
pubmed: 28826878